Protheragen Expands 13C/14C-Labeled Compound Portfolio for Metabolic and Pharmacokinetic Studies

Protheragen offers a wider variety of 13C/14C-labeled compounds, supporting research in metabolic pathways, pharmacokinetics, breath assays, and biochemical tracing. New York, USA - November 12, 2025 - Protheragen has expanded its 13C/14C-labeled compound portfolio to support research in metabolic pathways, pharmacokinetics, breath assays, and biochemical tracing. The expanded lineup improves options for high-accuracy molecular tracing and supports consistent data output in metabolism and drug d